Literature DB >> 17569618

Synergistic antitumor activity of immune strategies combined with radiation.

Hadley J Sharp1, Elizabeth K Wansley, Charlie T Garnett, Mala Chakraborty, Kevin Camphausen, Jeffrey Schlom, James W Hodge.   

Abstract

Since its discovery more than a hundred years ago, radiation has been used to treat cancer. In recent decades, advances in radiation technology have expanded the role and value of radiation in imaging and treating many forms of cancer. Currently, there is a growing interest in combining radiation with other modalities, such as immunotherapy, to treat a broad range of malignancies. This article reviews the use of standard and novel combinations of radiation therapy and immunotherapy to eradicate tumor cells. The combination of radiation therapy and immunotherapy holds particular promise as a strategy for cancer therapeutics for a variety of reasons. First, there is evidence that immunotherapy is most beneficial when employed early in the disease process and in combination with standard therapies. In addition, radiation may act synergistically with immunotherapy to enhance immune responses, inhibit immunosuppression, and/or alter the phenotype of tumor cells, thus rendering them more susceptible to immune-mediated killing. Finally, as monotherapies, both immunotherapy and radiation may be insufficient to eliminate tumor masses. However, following immunization with a cancer vaccine, the destruction of even a small percentage of tumor cells by radiation could result in cross-priming and presentation of tumor antigens to the immune system, thereby potentiating antitumor responses.

Entities:  

Mesh:

Year:  2007        PMID: 17569618     DOI: 10.2741/2436

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  10 in total

Review 1.  The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors.

Authors:  James W Hodge; Andressa Ardiani; Benedetto Farsaci; Anna R Kwilas; Sofia R Gameiro
Journal:  Semin Oncol       Date:  2012-06       Impact factor: 4.929

Review 2.  Radioimmunotherapy of solid tumors: searching for the right target.

Authors:  Hong Song; George Sgouros
Journal:  Curr Drug Deliv       Date:  2011-01       Impact factor: 2.565

3.  mRNA Expression Profiles for Prostate Cancer following Fractionated Irradiation Are Influenced by p53 Status.

Authors:  Charles B Simone; Molykutty John-Aryankalayil; Sanjeewani T Palayoor; Adeola Y Makinde; David Cerna; Michael T Falduto; Scott R Magnuson; C Norman Coleman
Journal:  Transl Oncol       Date:  2013-10-01       Impact factor: 4.243

4.  Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization.

Authors:  Yi T Koh; Andrew Gray; Sean A Higgins; Bolyn Hubby; W Martin Kast
Journal:  Prostate       Date:  2009-05-01       Impact factor: 4.104

5.  Concurrent dendritic cell vaccine and strontium-89 radiation therapy in the management of multiple bone metastases.

Authors:  J Liu; J Li; Y Fan; K Chang; X Yang; W Zhu; X Wu; Yan Pang
Journal:  Ir J Med Sci       Date:  2014-05-30       Impact factor: 1.568

Review 6.  Temperature as a modulator of the gut microbiome: what are the implications and opportunities for thermal medicine?

Authors:  Bonnie L Hylander; Elizabeth A Repasky
Journal:  Int J Hyperthermia       Date:  2019-11       Impact factor: 3.914

7.  Sub-lethal irradiation of human colorectal tumor cells imparts enhanced and sustained susceptibility to multiple death receptor signaling pathways.

Authors:  Victoria Ifeadi; Charlie Garnett-Benson
Journal:  PLoS One       Date:  2012-02-28       Impact factor: 3.240

8.  In situ vaccination with CD204 gene-silenced dendritic cell, not unmodified dendritic cell, enhances radiation therapy of prostate cancer.

Authors:  Chunqing Guo; Huanfa Yi; Xiaofei Yu; Daming Zuo; Jie Qian; Gary Yang; Barbara A Foster; John R Subjeck; Xiaolei Sun; Ross B Mikkelsen; Paul B Fisher; Xiang-Yang Wang
Journal:  Mol Cancer Ther       Date:  2012-08-15       Impact factor: 6.261

9.  Partial depletion of regulatory T cells does not influence the inflammation caused by high dose hemi-body irradiation.

Authors:  Shihong Ma; James A Richardson; Andrew Bitmansour; Timothy D Solberg; Rajesh Pidikiti; Kwang Song; Strahinja Stojadinovic; Ellen S Vitetta; Jeffrey J Meyer
Journal:  PLoS One       Date:  2013-02-11       Impact factor: 3.240

Review 10.  Reduced Number of Lymphocytes by X-ray Irradiation: A Problem in a Combination Therapy Trial that Elicits the Abscopal Effect in Preclinical Studies Using Electron Beam Irradiation.

Authors:  Shiro Kanegasaki; Takashi Yamashita; Tomoko Tsuchiya
Journal:  Cureus       Date:  2019-02-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.